Top Page
Shanghai Fosun Pharmaceutical (Group) Co
(OTC:2196)
Shanghai Fosun Pharmaceutical (Group) Co (2196) vs. S&P 500 (SPY)
Shanghai Fosun Pharmaceutical (Group) Co Business Overview & Revenue Model
Shanghai Fosun Pharmaceutical (Group) Co Financial Statement Overview
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 40.33B | 41.07B | 41.40B | 43.95B | 39.01B | 30.31B | Gross Profit |
| 19.12B | 19.70B | 19.68B | 20.78B | 18.78B | 16.88B | EBIT |
| 4.58B | 4.25B | 3.31B | 8.30B | 6.31B | 4.72B | EBITDA |
| 6.22B | 8.60B | 7.55B | 7.87B | 8.70B | 6.89B | Net Income Common Stockholders |
| 2.92B | 2.77B | 2.39B | 3.73B | 4.73B | 3.66B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 16.07B | 16.12B | 15.58B | 17.17B | 14.55B | 11.93B | Total Assets |
| 117.99B | 117.46B | 113.47B | 107.16B | 93.29B | 83.69B | Total Debt |
| 32.06B | 31.70B | 30.28B | 30.25B | 24.25B | 24.01B | Net Debt |
| 18.35B | 18.17B | 16.59B | 14.01B | 13.94B | 14.05B | Total Liabilities |
| 57.14B | 57.53B | 56.85B | 53.05B | 44.92B | 37.70B | Stockholders Equity |
| 47.92B | 47.26B | 45.68B | 44.58B | 39.19B | 37.00B |
| Cash Flow | Free Cash Flow | ||||
| 257.89M | 66.79M | ― | ― | ― | ― | Operating Cash Flow |
| 989.69M | 4.48B | 3.41B | 4.22B | 3.95B | 2.58B | Investing Cash Flow |
| 210.24M | ― | -3.82B | ― | ― | ― | Financing Cash Flow |
| 991.93M | ― | ― | 4.43B | ― | 1.47B |
Shanghai Fosun Pharmaceutical (Group) Co Technical Analysis
Shanghai Fosun Pharmaceutical (Group) Co Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $66.00B | 14.36 | 13.20% | 5.99% | -9.60% | -27.18% | |
74 Outperform | HK$30.86B | 10.52 | 14.56% | 5.66% | -5.37% | 6.28% | |
70 Outperform | HK$327.51M | 6.91 | 6.61% | 6.26% | -3.59% | 4.81% | |
66 Neutral | $69.96B | 36.85 | 6.14% | 1.54% | 7.63% | -24.23% | |
65 Neutral | $61.60B | 12.24 | 6.22% | 1.97% | -2.82% | 11.93% | |
62 Neutral | HK$30.78B | 8.47 | 5.65% | ― | ― | ||
52 Neutral | $5.15B | 3.56 | -42.52% | 2.83% | 14.56% | -0.50% |
Shanghai Fosun Pharmaceutical (Group) Co Corporate Events
Shanghai Fosun Pharmaceutical has announced the establishment of a Target Fund through a partnership with Suzhou Junming, Henan Fujian, Yujian Biomedical, and Zhengzhou Airport Capital. The fund, with a proposed size of RMB2,500 million, aims to invest in innovative enterprises within the medical and life sciences sectors. This move is part of a connected transaction under the Hong Kong Listing Rules, which requires reporting and announcement but not independent shareholder approval.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has released its unaudited financial report for the first quarter of 2025, ending on March 31. The report, prepared in accordance with PRC Accounting Standards, assures stakeholders of the truthfulness and accuracy of the financial information, as confirmed by the company’s senior management.
Shanghai Fosun Pharmaceutical has announced significant changes in its board of directors, including the resignation of its chairman and other key members, as well as the appointment of new directors. These changes are part of the company’s strategic realignment to enhance its governance structure and align with the newly amended Company Law of the PRC. The proposed amendments to the Articles of Association and the appointment of new board members are expected to strengthen the company’s leadership and support its long-term growth objectives.
Shanghai Fosun Pharmaceutical has announced the composition of its board of directors, which includes 12 members with roles spanning executive, non-executive, and independent non-executive positions. The announcement details the membership of board committees, which are integral to the company’s strategic, audit, nomination, remuneration, and environmental governance functions, indicating a structured approach to corporate governance.
Shanghai Fosun Pharmaceutical has successfully completed the issuance of its first tranche of medium-term notes for 2025, valued at RMB 0.5 billion. These notes, aimed at supporting scientific and technological innovation, have a fixed interest rate of 3.10% and are set to mature in two years, with the Bank of Shanghai as the leading underwriter.
Shanghai Fosun Pharmaceutical announced the formation of a partnership involving its subsidiary Fosun Pingyao and other entities, including Shanghai Fujian, Fosun High Tech, and Fuyao Zhigang, to establish Henan Fujian with a total capital contribution of RMB10 million. This connected transaction, subject to Hong Kong Listing Rules, aims to enhance Fosun’s strategic positioning by creating an associated company, reflecting its ongoing efforts to expand its business operations and strengthen its market influence.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced that its board of directors will hold a meeting on April 29, 2025, to consider and approve the company’s first quarterly results for the period ending March 31, 2025. This meeting and subsequent publication of results could provide insights into the company’s financial health and operational performance, potentially impacting its market positioning and stakeholder interests.
Shanghai Fosun Pharmaceutical announced the disposal of a portion of its equity interest in its subsidiary, Shanghai Fujian, through an Equity Transfer Agreement with Fosun High Tech, Ms. Li Fan, and Ms. Guan Xiaohui. This transaction reduces the company’s stake in Shanghai Fujian from 100% to 45%, aligning with the Hong Kong Listing Rules as a connected transaction. The move is part of a strategic realignment, potentially impacting the company’s operational focus and stakeholder interests.
Shanghai Fosun Pharmaceutical announced the repurchase and cancellation of 897,140 restricted shares under its 2022 Restricted A Share Incentive Scheme, due to resignations and unmet performance indicators. This move will reduce the company’s total issued share capital and registered capital, reflecting a strategic adjustment in its incentive scheme to align with performance and participation changes.
Shanghai Fosun Pharmaceutical’s subsidiary, Fosun Pharma (Xuzhou) Co., Ltd., has received approval from the National Medical Products Administration to conduct a clinical trial for CMC-2310 Oral Soluble Film, a treatment for schizophrenia in adults and pediatric patients aged 13 and older. This approval marks a significant step in the company’s R&D efforts, having invested RMB 7.25 million in the drug’s development. The drug, with the same active ingredient, was previously approved for marketing in China in 2024, indicating the company’s ongoing commitment to expanding its pharmaceutical offerings.
Shanghai Fosun Pharmaceutical has entered into a Share Subscription Agreement with IFC, ADB, and United Health Insurance to increase its equity interest in United Health Insurance from 14.00% to 20.05%. This transaction, which involves a capital contribution of RMB270 million from each party, is part of Fosun’s strategy to strengthen its position in the healthcare sector, though it is classified as a connected transaction under Hong Kong Listing Rules due to Fosun High Tech’s substantial interest.
Shanghai Fosun Pharmaceutical has received approval from the National Association of Financial Market Institutional Investors for the registration of RMB4 billion in medium term notes and RMB6 billion in super short-term commercial papers. These financial instruments will be issued in tranches over a two-year period starting March 2025, with Bank of Shanghai and China Merchants Bank as joint lead underwriters. This strategic move is expected to enhance the company’s financial flexibility and support its capital needs, potentially strengthening its market position.
Shanghai Fosun Pharmaceutical reported its audited financial results for the year ending December 31, 2024, highlighting a slight decrease in revenue to RMB 40,910 million from RMB 41,249 million in 2023. Despite this, the company achieved a significant increase in operating profit, rising to RMB 2,780 million from RMB 1,100 million the previous year, and improved its net profit margin to 8.59%. These results reflect the company’s enhanced operational efficiency and strategic focus on profitability, which may positively impact its market positioning and stakeholder confidence.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced a final cash dividend of RMB 0.32 per share for the year ending December 31, 2024. This announcement reflects the company’s commitment to providing returns to its shareholders. The dividend will be subject to withholding tax rates depending on the residency status of shareholders, with non-resident enterprises and individuals facing a 10% tax, while mainland investors through the Stock Connect programs will incur a 20% tax. This decision underscores Fosun Pharma’s stable financial performance and its strategic focus on rewarding investors, potentially enhancing its attractiveness in the market.
Shanghai Fosun Pharmaceutical’s subsidiary, S-INFINITY Pharmaceuticals, has received approval from the National Medical Products Administration to commence a Phase II clinical trial for XH-S003 capsules, a small molecule inhibitor targeting paroxysmal nocturnal hemoglobinuria (PNH). This development marks a significant step in the company’s efforts to address rare blood disorders, potentially enhancing its market position and offering new treatment options for patients with complement-mediated diseases.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced a board meeting scheduled for March 25, 2025, to consider and approve the company’s final results for the year ending December 31, 2024. The meeting will also discuss the recommendation of a final dividend and other business matters, indicating a focus on financial performance and shareholder returns.
Shanghai Fosun Pharmaceutical’s subsidiary, Fosun Adgenvax, has received approval from China’s National Medical Products Administration to conduct a Phase I clinical trial for its 24-valent pneumococcal polysaccharide conjugate vaccine. This development marks a significant step in the company’s efforts to advance its vaccine portfolio, leveraging its proprietary platform technology to address infectious diseases caused by various pneumococcal serotypes.
Shanghai Fosun Pharmaceutical’s subsidiary, Jiangsu Xingsheng Xinhui Pharmaceutical, has received approval from China’s National Medical Products Administration to conduct clinical trials for XS-03 tablets. These tablets, intended for treating metastatic colorectal cancer with RAS mutations, will be tested in combination with existing standard treatments FOLFOX or FOLFIRI and bevacizumab. The approval marks a significant step in advancing the company’s oncology pipeline and could potentially enhance its positioning in the pharmaceutical industry.
Shanghai Fosun Pharmaceutical has announced the approval of Tenapanor Hydrochloride Tablets for controlling serum phosphorus levels in dialysis patients with chronic kidney disease. This approval by the National Medical Products Administration marks a significant step for Fosun Pharma, enhancing its product portfolio and potentially improving its market positioning in the treatment of CKD.
Shanghai Fosun Pharmaceutical announced that its subsidiary, Yaopharma Co., Ltd., has had its drug registration application for Bromhexine Hydrochloride Injection accepted by the National Medical Products Administration. This drug, intended for expectorant therapy in patients with difficulty in oral administration, marks a significant step in the company’s research and development efforts, with an investment of approximately RMB 1.64 million to date. The acceptance of this application could enhance Fosun Pharma’s market position and impact stakeholders positively by expanding its product offerings in the pharmaceutical industry.
Shanghai Fosun Pharmaceutical announced that its subsidiary, Suzhou Erye Pharmaceutical Co., Ltd., has received marketing registration approval from the National Medical Products Administration for Compound Sodium Picosulfate Granules. This approval is expected to enhance the company’s product offerings and strengthen its position in the pharmaceutical market, potentially benefiting stakeholders by expanding its portfolio and market reach.
Shanghai Fosun Pharmaceutical announced that Fosun Health, its subsidiary, has entered into a Capital Increase Agreement with several entities to enhance its equity interest in the Target from 57.5363% to 67.1872%. This strategic move, involving a capital contribution of RMB30 million, is categorized as a connected transaction under the Hong Kong Listing Rules, requiring reporting and announcement but exempt from independent shareholders’ approval. The transaction underscores Fosun’s ongoing expansion strategy within its operational framework, potentially strengthening its market positioning.
Shanghai Fosun Pharmaceutical announced the acceptance of drug registration applications for two of its subsidiary companies’ products by the National Medical Products Administration. This development marks a significant step for the company in expanding its pharmaceutical offerings, particularly with drugs targeting gram-negative bacterial infections and severe hypertension, potentially enhancing its market position.
Shanghai Fosun Pharmaceutical’s subsidiary, Zhejiang Xinghao Pengbo Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration to begin clinical trials for XH-S004 tablets, a class 1 chemical medicine aimed at treating chronic obstructive pulmonary disease. This development signifies Fosun Pharma’s continued commitment to advancing pharmaceutical research, with XH-S004 also being tested for other indications such as non-cystic fibrosis bronchiectasis, reflecting potential growth in its R&D investments.